CLDX Morgan Stanley raised the firm's price target on Celldex to $57 from $50 and keeps an Overweight rating on the shares. Barzolvolimab demonstrated best-in-disease efficacy in EMBARQ-CSU, while its safety proved to be "the primary source of debate," the analyst tells investors. Management sees a black box warning as unlikely, says the analyst, who believes the safety profile remains "manageable" and continues to see "a blockbuster opportunity in chronic urticaria."
CLDX Morgan Stanley raised the firm's price target on Celldex to $57 from $50 and keeps an Overweight rating on the shares. Barzolvolimab demonstrated best-in-disease efficacy in EMBARQ-CSU, while its safety proved to be "the primary source of debate," the analyst tells investors. Management sees a black box warning as